Reverence Home Health And Hospice Location: 5220 Lovers Ln, Suite 130, Portage, Michigan 49002 Ratings: Phone: (269) 343-1396 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Advisacare Solutions Of Kalamazoo Location: 5401 Portage Rd, Suite 1, Portage, Michigan 49002 Ratings: Phone: (269) 226-9363 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Paragon Home Healthcare Location: 601 E Centre Ave, Portage, Michigan 49002 Ratings: Phone: (269) 343-0900 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Legacy Home Healthcare Location: 1615 W Centre Ave, Suite 201, Portage, Michigan 49024 Ratings: Phone: (269) 888-2333 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
Pinnacle Senior Care Location: 2725 Airview Blvd, Suite 105b, Portage, Michigan 49002 Ratings: Phone: (269) 743-4650 Health Services: Nursing Care, Physical Therapy, Occupational Therapy, Speech Pathology, Medical Social Services, Home Health Aide |
News Archive
Kaiser Permanente Colorado is one of only three health plans in the nation to receive a top honor for excellence in medication safety. The award, issued by the Pharmacy Quality Alliance, recognizes Kaiser Permanente's outstanding performance on medication safety measures included in the Centers for Medicare and Medicaid Services (CMS) new 5-star rating program.
NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium.
The Annals of the American Thoracic Society has released a comprehensive supplement on the 56th annual Thomas L. Petty Aspen Lung Conference entitled "The Lung Microbiome: A New Frontier in Pulmonary Medicine."
Phase III clinical study comparing placebo to rimonabant, the first agent in a new therapeutic class known as selective cannabinoid type 1 (CB1) blockers, showed that overweight or obese people taking rimonabant 20mg once daily benefited from a significant reduction in their body weight
› Verified 8 days ago